{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:19Z","timestamp":1792787959555,"version":"4.5.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1053\/j.gastro.2026.08.025","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:32:12Z","timestamp":1792661532000},"page":"817-839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["AGA\/AASLD Clinical Practice Guideline on Management of Primary Biliary Cholangitis"],"prefix":"10.1053","volume":"171","author":[{"given":"Cynthia","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlyn J.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Assis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Sedki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahnaz","family":"Sultan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Taddei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Bittermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perica","family":"Davitkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2026.08.025_bib1","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","article-title":"Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases","volume":"75","author":"Lindor","year":"2022","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.08.025_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"The diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib3","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jhep.2026.03.038","article-title":"EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis","volume":"85","year":"2026","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib4","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.cgh.2020.06.025","article-title":"Effects of primary biliary cholangitis on quality of life and health care costs in the United Kingdom","volume":"19","author":"Rice","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1572-0241.2003.07257.x","article-title":"Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis","volume":"98","author":"Muratori","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.08.025_bib6","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.08.025_bib7","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/ajg.2017.440","article-title":"Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome","volume":"113","author":"Harms","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.08.025_bib8","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.08.025_bib9","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/apt.70120","article-title":"Longitudinal relationship between elevated liver biochemical tests and negative clinical outcomes in primary biliary cholangitis: a population-based study","volume":"61","author":"Kowdley","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.08.025_bib10","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jhep.2022.06.017","article-title":"Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis","volume":"77","author":"Corpechot","year":"2022","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2025.09.024","article-title":"Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis","volume":"84","author":"Wong","year":"2026","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib12","article-title":"Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: data from the GLIMMER study","volume":"9","author":"Smith","year":"2025","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2026.08.025_bib13","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s10620-022-07581-x","article-title":"Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis","volume":"68","author":"Mayo","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2026.08.025_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S2468-1253(25)00257-2","article-title":"Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases","volume":"11","author":"Koc","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/LVT.0000000000000419","article-title":"Recurrence of autoimmune liver diseases after liver transplantation: review and expert opinion statement","volume":"31","author":"Montano-Loza","year":"2025","journal-title":"Liver Transpl"},{"key":"10.1053\/j.gastro.2026.08.025_bib16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cgh.2013.02.001","article-title":"The AGA Institute process for developing clinical practice guidelines part one: grading the evidence","volume":"11","author":"Sultan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib17","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","article-title":"Primary biliary cholangitis","volume":"404","author":"Tanaka","year":"2024","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2026.08.025_bib18","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","article-title":"Primary biliary cholangitis","volume":"396","author":"Lleo","year":"2020","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2026.08.025_bib20","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/s11336-014-9430-0","article-title":"Meta-analysis of diagnostic accuracy and ROC curves with covariate adjusted semiparametric mixtures","volume":"80","author":"Doebler","year":"2015","journal-title":"Psychometrika"},{"key":"10.1053\/j.gastro.2026.08.025_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"10.1053\/j.gastro.2026.08.025_bib22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/publications14010004","article-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","volume":"14","author":"Wells","year":"2026","journal-title":"Publications"},{"key":"10.1053\/j.gastro.2026.08.025_bib23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2026.08.025_bib24","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1053\/j.gastro.2026.08.025_bib25","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2025.03.034","article-title":"Large language model-supported systematic reviews to augment clinical guideline development: an American Gastroenterological Association pilot","volume":"169","author":"Chung","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.08.025_bib27","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8959103","article-title":"Meta-analysis of antinuclear antibodies in the diagnosis of antimitochondrial antibody-negative primary biliary cholangitis","volume":"2019","author":"Zhang","year":"2019","journal-title":"Gastroenterol Res Pract"},{"key":"10.1053\/j.gastro.2026.08.025_bib28","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/j.1365-2036.2006.03172.x","article-title":"Antinuclear antibodies giving the 'multiple nuclear dots' or the 'rim-like\/membranous' patterns: diagnostic accuracy for primary biliary cirrhosis","volume":"24","author":"Granito","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.08.025_bib29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/ajg.2009.596","article-title":"PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis","volume":"105","author":"Granito","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.08.025_bib30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/liv.14688","article-title":"Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis","volume":"41","author":"Haldar","year":"2021","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2026.08.025_bib31","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.cgh.2009.07.012","article-title":"Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease","volume":"7","author":"Milkiewicz","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2023.117219","article-title":"Presence of anti-gp210 or anti-sp100 antibodies in AMA-positive patients may help support a diagnosis of primary biliary cholangitis","volume":"540","author":"Jaskowski","year":"2023","journal-title":"Clin Chim Acta"},{"key":"10.1053\/j.gastro.2026.08.025_bib33","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1046\/j.1365-2249.1998.00735.x","article-title":"Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status","volume":"114","author":"Invernizzi","year":"1998","journal-title":"Clin Exp Immunol"},{"key":"10.1053\/j.gastro.2026.08.025_bib34","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12016-010-8234-y","article-title":"Overcoming a \"probable\" diagnosis in antimitochondrial antibody negative primary biliary cirrhosis: study of 100 sera and review of the literature","volume":"42","author":"Bizzaro","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1053\/j.gastro.2026.08.025_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.24040","article-title":"Clinical impact of antibodies to Sp100 on a bacterial infection in patients with primary biliary cholangitis","volume":"35","author":"Himoto","year":"2021","journal-title":"J Clin Lab Anal"},{"key":"10.1053\/j.gastro.2026.08.025_bib36","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1007\/s10620-011-1756-1","article-title":"Prevalence of autoimmune liver disease related autoantibodies in Chinese patients with primary biliary cirrhosis","volume":"56","author":"Hu","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1053\/j.gastro.2026.08.025_bib37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3390\/diagnostics11040587","article-title":"Analysis of autoantibodies against promyelocytic leukemia nuclear body components and biochemical parameters in sera of patients with primary biliary cholangitis","volume":"11","author":"Bauer","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.gastro.2026.08.025_bib38","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1515\/cclm-2020-0122","article-title":"Evaluation of a novel extended automated particle-based multi-analyte assay for the detection of autoantibodies in the diagnosis of primary biliary cholangitis","volume":"58","author":"Villalta","year":"2020","journal-title":"Clin Chem Lab Med"},{"key":"10.1053\/j.gastro.2026.08.025_bib39","first-page":"209","article-title":"[Diagnostic significance of autoantibodies in patients with primary biliary cirrhosis]","volume":"44","author":"Xiao","year":"2012","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1053\/j.gastro.2026.08.025_bib40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.5387\/fms.58.107","article-title":"Autoantibodies by line immunoassay in patients with primary biliary cirrhosis","volume":"58","author":"Saito","year":"2012","journal-title":"Fukushima J Med Sci"},{"key":"10.1053\/j.gastro.2026.08.025_bib41","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3390\/biomedicines10040801","article-title":"Diagnostic and clinical value of specific autoantibodies against Kelch-like 12 peptide and nuclear envelope proteins in patients with primary biliary cholangitis","volume":"10","author":"Bauer","year":"2022","journal-title":"Biomedicines"},{"key":"10.1053\/j.gastro.2026.08.025_bib42","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.mayocp.2020.01.015","article-title":"Cholestatic liver diseases: a primer for generalists and subspecialists","volume":"95","author":"Hilscher","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.gastro.2026.08.025_bib43","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/apt.70614","article-title":"Dual positivity for AMA\/AMA-M2 and anti-gp210\/sp100 shows highest diagnostic value for primary biliary cholangitis","volume":"63","author":"Liu","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.08.025_bib44","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDra2300232","article-title":"Assessing diagnostic performance","volume":"3","author":"Cosby","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1053\/j.gastro.2026.08.025_bib45","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/his.12384","article-title":"Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication","volume":"65","author":"Chan","year":"2014","journal-title":"Histopathology"},{"key":"10.1053\/j.gastro.2026.08.025_bib46","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMra1610570","article-title":"Use of liver imaging and biopsy in clinical practice","volume":"377","author":"Tapper","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.08.025_bib47","first-page":"CD000551","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"12","author":"Rudic","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2026.08.025_bib48","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/gutjnl-2019-319057","article-title":"Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis","volume":"69","author":"Harms","year":"2020","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.08.025_bib49","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","author":"Gluud","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.gastro.2026.08.025_bib50","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000004054","article-title":"Evolving concepts of treatment targets for primary biliary cholangitis: a global perspective","author":"Bowlus","year":"2026","journal-title":"Am J Gastroenterol."},{"key":"10.1053\/j.gastro.2026.08.025_bib51","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib52","article-title":"Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis","volume":"6","author":"Roberts","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1053\/j.gastro.2026.08.025_bib53","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MCG.0000000000001433","article-title":"Liver stiffness measured by either magnetic resonance or transient elastography is associated with liver fibrosis and is an independent predictor of outcomes among patients with primary biliary cholangitis","volume":"55","author":"Osman","year":"2021","journal-title":"J Clin Gastroenterol"},{"key":"10.1053\/j.gastro.2026.08.025_bib54","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12072-023-10587-w","article-title":"Prognostic significance of liver stiffness in patients with primary biliary cholangitis: validation of Baveno VII criteria","volume":"18","author":"Ding","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1053\/j.gastro.2026.08.025_bib55","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.dld.2020.02.002","article-title":"Assessment of biopsy proven liver fibrosis by two-dimensional shear wave elastography in patients with primary biliary cholangitis","volume":"52","author":"Yan","year":"2020","journal-title":"Dig Liver Dis"},{"key":"10.1053\/j.gastro.2026.08.025_bib56","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.21037\/qims-21-657","article-title":"Shear wave elastography and shear wave dispersion imaging in primary biliary cholangitis-a pilot study","volume":"12","author":"Schulz","year":"2022","journal-title":"Quant Imaging Med Surg"},{"key":"10.1053\/j.gastro.2026.08.025_bib57","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/00365521.2021.1928277","article-title":"Liver stiffness measurements by 2-dimensional shear wave elastography compared to histological and ultrasound parameters in primary biliary cholangitis","volume":"56","author":"Manesis","year":"2021","journal-title":"Scand J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.08.025_bib58","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hep.22056","article-title":"Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage","volume":"47","author":"Sagir","year":"2008","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.08.025_bib59","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/j.cgh.2024.10.020","article-title":"Noninvasive assessment of portal hypertension in patients with primary biliary cholangitis is affected by severity of cholestasis","volume":"23","author":"Calvaruso","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib60","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/hep.31810","article-title":"Accuracy of transient elastography in assessing fibrosis at diagnosis in naive patients with primary biliary cholangitis: a dual cut-off approach","volume":"74","author":"Cristoferi","year":"2021","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.08.025_bib61","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.cgh.2024.06.035","article-title":"Dynamics of liver stiffness measurement and clinical course of primary biliary cholangitis","volume":"22","author":"Lam","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib62","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jhep.2024.03.015","article-title":"Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure","volume":"81","author":"Semmler","year":"2024","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib63","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/HEP.0000000000000891","article-title":"Comparing serial and current liver stiffness measurements to predict decompensation in compensated advanced chronic liver disease patients","volume":"81","author":"Wong","year":"2025","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.08.025_bib64","doi-asserted-by":"crossref","first-page":"S-1694","DOI":"10.1016\/S0016-5085(26)04118-1","article-title":"Disease control as evidenced by longitudinal transient elastography measurements in the ASSURE study: 36 months of treatment with seladelpar is associated with stable or improved liver stiffness in patients with primary biliary cholangitis","volume":"170","author":"Bowlus","year":"2026","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.08.025_bib65","article-title":"Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world","volume":"7","author":"Terracciani","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1053\/j.gastro.2026.08.025_bib66","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/HEP.0000000000001465","article-title":"Comparative effectiveness of peroxisome proliferator-activated receptor agonists as second-line therapies for primary biliary cholangitis: a systematic review and network meta-analysis","volume":"83","author":"Martins","year":"2026","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.08.025_bib67","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00535-002-1102-7","article-title":"Bezafibrate treatment: a new medical approach for PBC patients?","volume":"38","author":"Kanda","year":"2003","journal-title":"J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.08.025_bib68","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1872-034X.2007.00305.x","article-title":"The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study","volume":"38","author":"Iwasaki","year":"2008","journal-title":"Hepatol Res"},{"key":"10.1053\/j.gastro.2026.08.025_bib69","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.08.025_bib70","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib71","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/HEP.0000000000000395","article-title":"Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study","volume":"78","author":"Hirschfield","year":"2023","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.08.025_bib72","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.08.025_bib73","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2026.08.025_bib74","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2022.02.033","article-title":"A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis","volume":"77","author":"Bowlus","year":"2022","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib75","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.14309\/ajg.0000000000003603","article-title":"Long-term efficacy and safety of selective PPARdelta agonist seladelpar in primary biliary cholangitis: ASSURE interim study results","volume":"121","author":"Levy","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.08.025_bib76","article-title":"FRI-317 Pharmacokinetics, safety, and tolerability of seladelpar in people with renal impairment","volume":"582","author":"Zhou","year":"2025","journal-title":"J Hepatol"},{"issue":"Suppl 4","key":"10.1053\/j.gastro.2026.08.025_bib77","first-page":"A35.1","article-title":"P34 Initial clinical response and safety of elafibranor in primary biliary cholangitis: a multi-centre pharmacist-led real-world evaluation","volume":"4","author":"Jones","year":"2025","journal-title":"Gut"},{"issue":"Suppl 4","key":"10.1053\/j.gastro.2026.08.025_bib78","first-page":"A32.2","article-title":"P30 Treatment with elafibranor has no impact on bone health in patients with primary biliary cholangitis (PBC)","volume":"74","author":"Schattenberg","year":"2025","journal-title":"Gut"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2026.08.025_bib79","article-title":"P350 Safety, tolerability, and pharmacokinetic effects of elafibranor co administration with simvastatin","volume":"73","author":"Pedret-Dunn","year":"2024","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.08.025_bib80","article-title":"P201 Bezafibrate as second line treatment in patients with primary biliary cholangitis: a real world experience","volume":"70","author":"McCabe","year":"2021","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2026.08.025_bib81","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for Itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.08.025_bib82","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.hepres.2004.04.001","article-title":"Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis","volume":"29","author":"Itakura","year":"2004","journal-title":"Hepatol Res"},{"key":"10.1053\/j.gastro.2026.08.025_bib83","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.14309\/ajg.0000000000002238","article-title":"Effectiveness of fenofibrate in treatment-naive patients with primary biliary cholangitis: a randomized clinical trial","volume":"118","author":"Liu","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2026.08.025_bib84","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221114198","article-title":"A randomized, controlled trial on fenofibrate in primary biliary cholangitis patients with incomplete response to ursodeoxycholic acid","volume":"13","author":"Li","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1053\/j.gastro.2026.08.025_bib85","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/hep4.2103","article-title":"Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid","volume":"6","author":"Ding","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2026.08.025_bib86","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/cpt.1930","article-title":"Fenofibrate improves liver function and reduces the toxicity of the bile acid pool in patients with primary biliary cholangitis and primary sclerosing cholangitis who are partial responders to ursodiol","volume":"108","author":"Ghonem","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 2","key":"10.1053\/j.gastro.2026.08.025_bib87","first-page":"65","article-title":"Fibrates seem to be equally effective as second-line therapy in primary biliary cholangitis, with biochemical response plateauing at 6 months","volume":"30","author":"Can\u00e7ado","year":"2025","journal-title":"Ann Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib88","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.cgh.2022.07.038","article-title":"UK-wide multicenter evaluation of second-line therapies in primary biliary cholangitis","volume":"21","author":"Abbas","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib89","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/liv.14165","article-title":"Additional fibrate treatment in UDCA-refractory PBC patients","volume":"39","author":"Chung","year":"2019","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2026.08.025_bib90","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.08.025_bib91","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/apt.17755","article-title":"Open-label, clinical trial extension: two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis","volume":"59","author":"Mayo","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2026.08.025_bib92","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","volume":"75","author":"Tanaka","year":"2021","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib93","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/HEP.0000000000000529","article-title":"Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: to what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?","volume":"79","author":"Corpechot","year":"2024","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.08.025_bib94","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000003973","article-title":"Impact of alkaline phosphatase normalization on complication-free survival in primary biliary cholangitis","author":"Reddy","year":"2026","journal-title":"Am J Gastroenterol."},{"key":"10.1053\/j.gastro.2026.08.025_bib95","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.cgh.2022.10.032","article-title":"GLIMMER: a randomized phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus","volume":"21","author":"Levy","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib96","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2468-1253(25)00192-X","article-title":"Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Hirschfield","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib97","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/hepr.13895","article-title":"Japanese subgroup analysis of GLIMMER: A global Phase IIb study of linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis","volume":"53","author":"Tanaka","year":"2023","journal-title":"Hepatol Res"},{"key":"10.1053\/j.gastro.2026.08.025_bib98","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib99","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-026-03694-1","article-title":"Meaningful improvement thresholds for pruritus and sleep disturbance in PBC using the worst itch and sleep interference numerical rating scales.","author":"Currie","year":"2026","journal-title":"Adv Ther"},{"key":"10.1053\/j.gastro.2026.08.025_bib100","doi-asserted-by":"crossref","first-page":"S\u20101820","DOI":"10.1016\/S0016-5085(25)05055-3","article-title":"Mo1622: Determining clinically meaningful thresholds for patient-reported outcomes of pruritus in primary biliary cholangitis","volume":"169","author":"Shamseddine","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2026.08.025_bib101","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.08.025_bib102","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/bcp.70277","article-title":"Ileal bile acid transporter inhibitors in Alagille syndrome and progressive familial intrahepatic cholestasis: a systematic review into dose-response","volume":"92","author":"de Groot","year":"2026","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/j.gastro.2026.08.025_bib103","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/HEP.0000000000001430","article-title":"Pretreatment serum bile acid composition and predictability of subsequent response to odevixibat in patients with bile salt export pump (BSEP) deficiency","volume":"83","author":"Nomden","year":"2026","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2026.08.025_bib104","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jhep.2020.03.043","article-title":"Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis","volume":"73","author":"Corpechot","year":"2020","journal-title":"J Hepatol"},{"key":"10.1053\/j.gastro.2026.08.025_bib105","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep4.1037","article-title":"Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: a Japanese multicenter retrospective study","volume":"1","author":"Kogiso","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1053\/j.gastro.2026.08.025_bib106","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jhep.2015.07.038","article-title":"Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence","volume":"63","author":"Bosch","year":"2015","journal-title":"J Hepatol"},{"issue":"Suppl 2","key":"10.1053\/j.gastro.2026.08.025_bib107","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1002\/lt.21916","article-title":"Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation","volume":"15","author":"Duclos-Vallee","year":"2009","journal-title":"Liver Transpl"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650852607232X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001650852607232X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:08:55Z","timestamp":1792786135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001650852607232X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":105,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S001650852607232X"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2026.08.025","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AGA\/AASLD Clinical Practice Guideline on Management of Primary Biliary Cholangitis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2026.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Gastroenterological Association Institute and American Association for the Study of Liver Diseases. Published by Elsevier Inc on behalf of American Gastroenterological Association Institute and by Wolters Kluwer Health on behalf of American Association for the Study of Liver Diseases. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}